CFM
FHTX icon

Catalyst Funds Management’s Foghorn Therapeutics FHTX Stock Holding History

Catalyst Funds Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$9.31K – 678
2024
Q3 		$9.31K Buy
+1,000
New +$7.24K ﹤0.01% 1195

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's FHTX Position: Q4 2024 in Review

Catalyst Funds Management sold out of Foghorn Therapeutics (FHTX) in Q4 2024, closing a stake of 1,000 shares — an estimated $9.31K sold.

Catalyst Funds Management first reported a position in FHTX in Q3 2024 and held it in 1 quarter. The position peaked at $9.31K in Q3 2024. 87 funds tracked by Wall St. Rank hold FHTX as of Q4 2024.

  • Catalyst Funds Management reported no remaining Foghorn Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,000 Foghorn Therapeutics shares in Q4 2024, an estimated $9.31K.
  • Catalyst Funds Management first reported a position in Foghorn Therapeutics in Q3 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Foghorn Therapeutics position peaked at $9.31K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.